title: MHC class I antigen presentation of DRiP-derived peptides from a model antigen is not dependent on the AAA ATPase p97.
abstract: CD8(+) T cells are responsible for killing cells of the body that have become infected or oncogenically transformed. In order to do so, effector CD8(+) T cells must recognize their cognate antigenic peptide bound to a MHC class I molecule that has been directly presented by the target cell. Due to the rapid nature of antigen presentation, it is believed that antigenic peptides are derived from a subset of newly synthesized proteins which are degraded almost immediately following synthesis and termed Defective Ribosomal Products or DRiPs. We have recently reported on a bioassay which can distinguish antigen presentation of DRiP substrates from other forms of rapidly degraded proteins and found that poly-ubiquitin chain disassembly may be necessary for efficient DRiP presentation. The AAA ATPase p97 protein is necessary for efficient cross-presentation of antigens on MHC class I molecules and plays an important role in extracting mis-folded proteins from the endoplasmic reticulum. Here, we find that genetic ablation or chemical inhibition of p97 does not diminish DRiP antigen presentation to any great extent nor does it alter the levels of MHC class I molecules on the cell surface, despite our observations that p97 inhibition increased the levels of poly-ubiquitinated proteins in the cell. These data demonstrate that inhibiting poly-ubiquitin chain disassembly alone is insufficient to abolish DRiP presentation.
authors.affiliation: Department of Biomedical Sciences, Oregon State University, Corvallis, Oregon, United States of America.
authors.forename: Amy L
authors.initials: AL
authors.lastname: Palmer
authors.forename: Brian P
authors.initials: BP
authors.lastname: Dolan
mesh_terms: D000251:Adenosine Triphosphatases / Q000235:genetics / Q000276:immunology* / Q000378:metabolism; D000818:Animals; D017951:Antigen Presentation / Q000187:drug effects / Q000235:genetics / Q000276:immunology*; D000941:Antigens / Q000235:genetics / Q000276:immunology* / Q000378:metabolism; D015153:Blotting, Western; D002460:Cell Line; D045744:Cell Line, Tumor; D005260:Female; D005434:Flow Cytometry; D015395:Histocompatibility Antigens Class I / Q000235:genetics / Q000276:immunology* / Q000378:metabolism; D006801:Humans; D051379:Mice; D009687:Nuclear Proteins / Q000235:genetics / Q000276:immunology* / Q000378:metabolism; D010452:Peptide Biosynthesis / Q000187:drug effects / Q000235:genetics / Q000276:immunology; D010446:Peptide Fragments / Q000276:immunology* / Q000378:metabolism; D025821:Polyubiquitin / Q000235:genetics / Q000276:immunology / Q000378:metabolism; D011799:Quinazolines / Q000494:pharmacology; D011993:Recombinant Fusion Proteins / Q000235:genetics / Q000276:immunology / Q000378:metabolism; D012270:Ribosomes / Q000235:genetics / Q000276:immunology / Q000378:metabolism; D015398:Signal Transduction / Q000235:genetics / Q000276:immunology; D018800:Thy-1 Antigens / Q000235:genetics / Q000276:immunology / Q000378:metabolism; D057149:Ubiquitinated Proteins / Q000235:genetics / Q000276:immunology / Q000378:metabolism
chemical_list: D000941:Antigens; D015395:Histocompatibility Antigens Class I; C558357:N2,N4-dibenzylquinazoline-2,4-diamine; D009687:Nuclear Proteins; D010446:Peptide Fragments; D011799:Quinazolines; D011993:Recombinant Fusion Proteins; D018800:Thy-1 Antigens; D057149:Ubiquitinated Proteins; D025821:Polyubiquitin; D000251:Adenosine Triphosphatases; C404942:p97 ATPase